EVFM News and Press, Evofem Biosciences Inc. From 03/31/22

Evofem Presents Positive Encore Data in Sexually Transmitted Infections Impacting Women at the 2022 Academy of Managed Care Pharmacy Annual Meeting PR Newswire Phase 2B /3 AMPREVENCE Clinical Trial Concluded with Women Experiencing a 50 Percent Risk Reduction in ...

Shares of Evofem Biosciences (EVFM -7.1%) are down after the company's Q4 2021 results missed on the bottom line. Evofem's (NASDAQ:EVFM) net loss widened ~27% to $51.6M compared to the prior-year period. Revenue of $3.57M was a 2000% year-over-year increase. Total operating expenses in the qu...

Evofem Completes Enrollment in EVOGUARD Phase 3 Clinical Trial of EVO100 for Prevention of Chlamydia and Gonorrhea in Women -- EVOGUARD remains on track for topline data readout later this year -- U.S. regulatory submission planned for the first half of 2023 PR Newswire ...

Evofem Biosciences, Inc. (EVFM) Q4 2021 Earnings Conference Call March 4, 2022 4:30 PM ET Company Participants Amy Raskopf – Vice President-Investor Relations Saundra Pelletier – Chief Executive Officer, President and Executive Director Jay File – Chief Financial Officer ...

Evofem Biosciences press release (NASDAQ:EVFM): Q4 GAAP EPS of -$0.33 misses by $0.10. Revenue of $3.57M (+2000.0% Y/Y) beats by $0.21M. Reduced net cash burn rate to $16.8 million in the fourth quarter of 2021 versus $32.0 million in Q3. Strengthened the balance sheet with aggregate gross pr...

Evofem Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update -- Net product sales more than doubled in the fourth quarter of 2021 vs. third quarter of 2021 -- -- Net cash burn decreased to $16.8 million -- -- Completed enrol...

Evofem Biosciences (NASDAQ:EVFM) is scheduled to announce Q4 earnings results on Thursday, March 3rd, after market close. The consensus EPS Estimate is -$0.13 (+74.0% Y/Y) and the consensus Revenue Estimate is $3.36M (+1876.5% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward rev...

Evofem Biosciences to Report Fourth Quarter and Year-End 2021 Results and Provide Corporate Update on Thursday, March 3, 2022 -- Conference Call Scheduled for 4:30 p.m. ET - PR Newswire SAN DIEGO , Feb. 17, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., ...

FDA Awards QIDP Designation for Prevention of Chlamydia to Evofem Biosciences -- Adds Five Years of Market Exclusivity on Approval -- PR Newswire SAN DIEGO , Feb. 9, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) announced today that ...

Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...